CannPal Progressing Canine Cannabinoid Trials

0
2

Australia’s CannPal Animal Therapeutics Limited (ASX:CP1) has announced it has commenced its Phase 2A pilot dose determination study for its canine osteoarthritis treatment, CPAT-01, and is looking for dogs to participate. CannPal hopes CPAT-01 will prove to be an effective alternative to Non-Steroidal Anti-Inflammatory (NSAID) drugs. Arthritis in dogs is very common, with an estimated […]

The post CannPal Progressing Canine Cannabinoid Trials appeared first on Hemp Gazette.